Close up picture of microscope in the laboratory
Our Work

Latham & Watkins Advises on Intellia Therapeutics’ Public Offering of Common Stock

December 1, 2022
Firm represents the underwriter in the offering by the clinical-stage genome editing company.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, has announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of US$45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Intellia. Goldman Sachs & Co. LLC is the sole underwriter for the offering. The offering is expected to close on or about December 2, 2022, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriter in the offering with a capital markets team led by partners Nathan Ajiashvili and Peter Handrinos, with associates Sandy Kugbei, Egzon Sulejmani, and James Sullivan.